Dectrekumab/VAK 694

Drug Profile

Dectrekumab/VAK 694

Alternative Names: QAX-576/VAK-694; QBX-258; VAK-694/dectrekumab; VAK-694/QAX-576

Latest Information Update: 25 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 30 Jul 2015 Dectrekumab/VAK 694 is still in phase II trials for Asthma in the USA
  • 01 Feb 2012 Phase-II clinical trials in Asthma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top